(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 April 2023 (06.04.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/052407 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 47/36* (2006.01)
A61K 9/06 (2006.01) *A61K 47/38* (2006.01)
A61K 31/52 (2006.01) *A61P 17/02* (2006.01)
A61K 47/10 (2017.01)

(21) International Application Number:
PCT/EP2022/076952

(22) International Filing Date:
28 September 2022 (28.09.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
21199822.4 29 September 2021 (29.09.2021) EP

(71) Applicant: **TOPADUR PHARMA AG** [CH/CH]; Grabenstrasse 11A, 8952 Schlieren (CH).

(72) Inventors: **TENOR, Hermann**; c/o Topadur Pharma AG, Grabenstrasse 11A, 8952 Schlieren (CH). **LUDIN, Christian**; c/o Topadur Pharma AG, Grabenstrasse 11A, 8952 Schlieren (CH). **BOUVET, Raphael**; c/o Topadur Pharma AG, Grabenstrasse 11A, 8952 Schlieren (CH). **CRACOWSKI, Jean Luc**; c/o Topadur Pharma AG, Grabenstrasse 11A, 8952 Schlieren (CH).

(74) Agent: **SPERRLE, Martin**; Latscha Schöllhorn Partner AG, Grellingerstrasse 60, 4052 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: TOPICAL COMPOSITIONS OF 2-PHENYL-3,4-DIHYDROPYRROLO[2,L-F] [1,2,4]TRIAZINONE DERIVATIVES AND USES THEREOF



(I)

(57) Abstract: The present invention relates to a topical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein R_1 is ethyl or propyl, preferably propyl; R_2 is methyl or ethyl, preferably methyl; R_3 is ethyl or propyl, preferably propyl; X is N or CH, preferably CH; n is 1 or 2, preferably n=1; as well as to the uses of said topical compositions for the treatment of diseases or disorders mediated by PDE5 activity and/or NO related endothelial dysfunction, preferably of a disease or disorder of the skin mediated by PDE5 activity and/or NO related endothelial dysfunction, in a subject, preferably in a human, and particularly, for the treatment of ischemic skin ulcers, digital ulcers (DU) in systemic sclerosis, diabetic foot ulcer, leg ulcer, ischemic arterial ulcers, livedoid vasculopathy, Martorell hypertensive ischemic leg ulcer, thromboangiitis obliteragans (Buerger' s disease), sickle cell leg ulcer, all of the foregoing preferably for wound healing, further preferably for chronic wound healing.

WO 2023/052407 A1